Sue-Jean Lin - 24 Nov 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin
Issuer symbol
ARQT
Transactions as of
24 Nov 2025
Net transactions value
-$567,945
Form type
4
Filing time
25 Nov 2025, 18:27:29 UTC
Previous filing
16 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LIN SUE-JEAN Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin 25 Nov 2025 0001867788

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $155,789 +18,052 +68% $8.63 44,787 24 Nov 2025 Direct F1
transaction ARQT Common Stock Options Exercise $54,222 +7,220 +16% $7.51 52,007 24 Nov 2025 Direct F2
transaction ARQT Common Stock Sale $777,956 -25,272 -49% $30.78 26,735 24 Nov 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -18,052 -67% $0.000000 9,000 24 Nov 2025 Common Stock 18,052 $8.63 Direct F1
transaction ARQT Stock Option (right to buy) Options Exercise $0 -7,220 -59% $0.000000 5,000 24 Nov 2025 Common Stock 7,220 $7.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F2 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F3 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.